A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma.

Hee Yeon Kim, Jin Dong Kim, Si Hyun Bae, Jun Yong Park, Kwang Hyub Han, Hyun Young Woo, Jong Young Choi, Seung Kew Yoon, Byoung Kuk Jang, Jae Seok Hwang, Sang Gyune Kim, Young Seok Kim, Yeon Seok Seo, Hyung Joon Yim, Soon Ho Um, Liver Cancer Study Group Korean Liver Cancer Study Group

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Transarterial chemoembolization (TACE) has long been used as a palliative therapy for unresectable hepatocellular carcinoma (HCC). High-dose hepatic arterial infusion chemotherapy (HAIC) has showed favorable outcomes in patients with intractable, advanced HCC. The aim of this study was to compare the effectiveness and safety of high-dose HAIC and conventional TACE using doxorubicin for advanced HCC. The high-dose HAIC group comprised 36 patients who were enrolled prospectively from six institutions. The enrollment criteria were good liver function, main portal vein invasion (including vascular shunt), infiltrative type, bilobar involvement, and/or refractory to prior conventional treatment (TACE, radiofrequency ablation, or percutaneous ethanol injection), and documented progressive disease. Patients received 5-fluorouracil (500 mg/m(2) on days 1~3) and cisplatin (60 mg/m(2) on day 2 every 4 weeks) via an implantable port system. In the TACE group, 31 patients with characteristics similar to those in the high-dose HAIC group were recruited retrospectively from a single center. Patients underwent a transarterial infusion of doxorubicin every 4~8 weeks. Overall, 6 patients (8.9%) achieved a partial response and 20 patients (29.8%) had stable disease. The objective response rate (complete response+partial response) was significantly better in the high-dose HAIC group than in the TACE group (16.7% vs. 0%, P=0.030). Overall survival was longer in the high-dose HAIC group than in the TACE group (median survival, 193 vs. 119 days; P=0.026). There were no serious adverse effects in the high-dose HAIC group, while hepatic complications occurred more often in the TACE group. High-dose HAIC appears to improve the tumor response and survival outcome compared to conventional TACE using doxorubicin in patients with intractable, advanced HCC.

Original languageEnglish
Pages (from-to)355-361
Number of pages7
JournalThe Korean journal of hepatology
Volume16
Issue number4
DOIs
Publication statusPublished - 2010 Dec 1

Fingerprint

Doxorubicin
Hepatocellular Carcinoma
Drug Therapy
Liver
Survival
Portal Vein
Palliative Care
Fluorouracil
Cisplatin
Blood Vessels
Ethanol
Safety
Injections

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Kim, Hee Yeon ; Kim, Jin Dong ; Bae, Si Hyun ; Park, Jun Yong ; Han, Kwang Hyub ; Woo, Hyun Young ; Choi, Jong Young ; Yoon, Seung Kew ; Jang, Byoung Kuk ; Hwang, Jae Seok ; Kim, Sang Gyune ; Kim, Young Seok ; Seo, Yeon Seok ; Yim, Hyung Joon ; Um, Soon Ho ; Korean Liver Cancer Study Group, Liver Cancer Study Group. / A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma. In: The Korean journal of hepatology. 2010 ; Vol. 16, No. 4. pp. 355-361.
@article{319f92856a6e4a4b8987fbf597332732,
title = "A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma.",
abstract = "Transarterial chemoembolization (TACE) has long been used as a palliative therapy for unresectable hepatocellular carcinoma (HCC). High-dose hepatic arterial infusion chemotherapy (HAIC) has showed favorable outcomes in patients with intractable, advanced HCC. The aim of this study was to compare the effectiveness and safety of high-dose HAIC and conventional TACE using doxorubicin for advanced HCC. The high-dose HAIC group comprised 36 patients who were enrolled prospectively from six institutions. The enrollment criteria were good liver function, main portal vein invasion (including vascular shunt), infiltrative type, bilobar involvement, and/or refractory to prior conventional treatment (TACE, radiofrequency ablation, or percutaneous ethanol injection), and documented progressive disease. Patients received 5-fluorouracil (500 mg/m(2) on days 1~3) and cisplatin (60 mg/m(2) on day 2 every 4 weeks) via an implantable port system. In the TACE group, 31 patients with characteristics similar to those in the high-dose HAIC group were recruited retrospectively from a single center. Patients underwent a transarterial infusion of doxorubicin every 4~8 weeks. Overall, 6 patients (8.9{\%}) achieved a partial response and 20 patients (29.8{\%}) had stable disease. The objective response rate (complete response+partial response) was significantly better in the high-dose HAIC group than in the TACE group (16.7{\%} vs. 0{\%}, P=0.030). Overall survival was longer in the high-dose HAIC group than in the TACE group (median survival, 193 vs. 119 days; P=0.026). There were no serious adverse effects in the high-dose HAIC group, while hepatic complications occurred more often in the TACE group. High-dose HAIC appears to improve the tumor response and survival outcome compared to conventional TACE using doxorubicin in patients with intractable, advanced HCC.",
author = "Kim, {Hee Yeon} and Kim, {Jin Dong} and Bae, {Si Hyun} and Park, {Jun Yong} and Han, {Kwang Hyub} and Woo, {Hyun Young} and Choi, {Jong Young} and Yoon, {Seung Kew} and Jang, {Byoung Kuk} and Hwang, {Jae Seok} and Kim, {Sang Gyune} and Kim, {Young Seok} and Seo, {Yeon Seok} and Yim, {Hyung Joon} and Um, {Soon Ho} and {Korean Liver Cancer Study Group}, {Liver Cancer Study Group}",
year = "2010",
month = "12",
day = "1",
doi = "10.3350/kjhep.2010.16.4.355",
language = "English",
volume = "16",
pages = "355--361",
journal = "Clinical and molecular hepatology",
issn = "2287-2728",
publisher = "Korean Association for the Study of the Liver",
number = "4",

}

Kim, HY, Kim, JD, Bae, SH, Park, JY, Han, KH, Woo, HY, Choi, JY, Yoon, SK, Jang, BK, Hwang, JS, Kim, SG, Kim, YS, Seo, YS, Yim, HJ, Um, SH & Korean Liver Cancer Study Group, LCSG 2010, 'A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma.', The Korean journal of hepatology, vol. 16, no. 4, pp. 355-361. https://doi.org/10.3350/kjhep.2010.16.4.355

A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma. / Kim, Hee Yeon; Kim, Jin Dong; Bae, Si Hyun; Park, Jun Yong; Han, Kwang Hyub; Woo, Hyun Young; Choi, Jong Young; Yoon, Seung Kew; Jang, Byoung Kuk; Hwang, Jae Seok; Kim, Sang Gyune; Kim, Young Seok; Seo, Yeon Seok; Yim, Hyung Joon; Um, Soon Ho; Korean Liver Cancer Study Group, Liver Cancer Study Group.

In: The Korean journal of hepatology, Vol. 16, No. 4, 01.12.2010, p. 355-361.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma.

AU - Kim, Hee Yeon

AU - Kim, Jin Dong

AU - Bae, Si Hyun

AU - Park, Jun Yong

AU - Han, Kwang Hyub

AU - Woo, Hyun Young

AU - Choi, Jong Young

AU - Yoon, Seung Kew

AU - Jang, Byoung Kuk

AU - Hwang, Jae Seok

AU - Kim, Sang Gyune

AU - Kim, Young Seok

AU - Seo, Yeon Seok

AU - Yim, Hyung Joon

AU - Um, Soon Ho

AU - Korean Liver Cancer Study Group, Liver Cancer Study Group

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Transarterial chemoembolization (TACE) has long been used as a palliative therapy for unresectable hepatocellular carcinoma (HCC). High-dose hepatic arterial infusion chemotherapy (HAIC) has showed favorable outcomes in patients with intractable, advanced HCC. The aim of this study was to compare the effectiveness and safety of high-dose HAIC and conventional TACE using doxorubicin for advanced HCC. The high-dose HAIC group comprised 36 patients who were enrolled prospectively from six institutions. The enrollment criteria were good liver function, main portal vein invasion (including vascular shunt), infiltrative type, bilobar involvement, and/or refractory to prior conventional treatment (TACE, radiofrequency ablation, or percutaneous ethanol injection), and documented progressive disease. Patients received 5-fluorouracil (500 mg/m(2) on days 1~3) and cisplatin (60 mg/m(2) on day 2 every 4 weeks) via an implantable port system. In the TACE group, 31 patients with characteristics similar to those in the high-dose HAIC group were recruited retrospectively from a single center. Patients underwent a transarterial infusion of doxorubicin every 4~8 weeks. Overall, 6 patients (8.9%) achieved a partial response and 20 patients (29.8%) had stable disease. The objective response rate (complete response+partial response) was significantly better in the high-dose HAIC group than in the TACE group (16.7% vs. 0%, P=0.030). Overall survival was longer in the high-dose HAIC group than in the TACE group (median survival, 193 vs. 119 days; P=0.026). There were no serious adverse effects in the high-dose HAIC group, while hepatic complications occurred more often in the TACE group. High-dose HAIC appears to improve the tumor response and survival outcome compared to conventional TACE using doxorubicin in patients with intractable, advanced HCC.

AB - Transarterial chemoembolization (TACE) has long been used as a palliative therapy for unresectable hepatocellular carcinoma (HCC). High-dose hepatic arterial infusion chemotherapy (HAIC) has showed favorable outcomes in patients with intractable, advanced HCC. The aim of this study was to compare the effectiveness and safety of high-dose HAIC and conventional TACE using doxorubicin for advanced HCC. The high-dose HAIC group comprised 36 patients who were enrolled prospectively from six institutions. The enrollment criteria were good liver function, main portal vein invasion (including vascular shunt), infiltrative type, bilobar involvement, and/or refractory to prior conventional treatment (TACE, radiofrequency ablation, or percutaneous ethanol injection), and documented progressive disease. Patients received 5-fluorouracil (500 mg/m(2) on days 1~3) and cisplatin (60 mg/m(2) on day 2 every 4 weeks) via an implantable port system. In the TACE group, 31 patients with characteristics similar to those in the high-dose HAIC group were recruited retrospectively from a single center. Patients underwent a transarterial infusion of doxorubicin every 4~8 weeks. Overall, 6 patients (8.9%) achieved a partial response and 20 patients (29.8%) had stable disease. The objective response rate (complete response+partial response) was significantly better in the high-dose HAIC group than in the TACE group (16.7% vs. 0%, P=0.030). Overall survival was longer in the high-dose HAIC group than in the TACE group (median survival, 193 vs. 119 days; P=0.026). There were no serious adverse effects in the high-dose HAIC group, while hepatic complications occurred more often in the TACE group. High-dose HAIC appears to improve the tumor response and survival outcome compared to conventional TACE using doxorubicin in patients with intractable, advanced HCC.

UR - http://www.scopus.com/inward/record.url?scp=79959574567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959574567&partnerID=8YFLogxK

U2 - 10.3350/kjhep.2010.16.4.355

DO - 10.3350/kjhep.2010.16.4.355

M3 - Article

C2 - 21415578

AN - SCOPUS:79959574567

VL - 16

SP - 355

EP - 361

JO - Clinical and molecular hepatology

JF - Clinical and molecular hepatology

SN - 2287-2728

IS - 4

ER -